SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: JGoren who wrote (731)2/6/1999 7:43:00 PM
From: Lel H  Read Replies (2) | Respond to of 1906
 
NESP, which gave Amgen a boost when they won arbitration with JNJ, is a derivative of Epogen. It has a different sugar composition attached to the core protein. Even though it's a derivative, it's still a chemically distinct compound, and apparently requires fewer administrations than Epogen. Because of its arbitration victory, Amgen should be free to pursue other markets besides the kidney dialysis market (I think).


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News